Allegro Licenses Lung Cancer Testing IP from Boston University, University of Utah Foundation
June 29, 2011
Allegro Licenses Lung Cancer Testing IP from Boston University, University of Utah Foundation
The IP licensed by Allegro relates to a gene expression-based platform that detects common molecular responses that occur throughout the respiratory tract in current and former smokers with lung cancer.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Allegro Dx Licenses IP from BU, University of Utah Foundation for Lung Cancer Test
July 5, 2011 / BioArray News - Med BioGene Amends Licensing Deal with Precision; Updates Litigation Status
October 3, 2012 / GenomeWeb Daily News - Allegro Completes Enrollment for Validation Trial for BronchoGen Lung Cancer Risk Test, Anticipates Release in 2013
August 1, 2012 / Pharmacogenomics Reporter - UPDATE: Signal Genetics Makes Improved Offer to Market Med BioGene Test
March 23, 2011 / GenomeWeb Daily News - Med BioGene Inks LungExpress Alliance with Precision Therapeutics
March 1, 2011 / GenomeWeb Daily News